GTx Plunges Most Ever as Drug Fails to Meet Trial Goals

GTx Inc., a drugmaker that recorded no revenue last year, plunged the most ever after the company said an experimental treatment failed to meet its goals in studies to combat muscle-wasting in lung-cancer patients.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.